You are here: Industry Insights > Biogen

News List

Biogen and Eisai’s previously bleak Alzheimer’s study comes back with positive results fiercebiotech
July 09, 2018
A phase 2 Alzheimer’s trial—once nearly consigned to the heap of disappointing attempts against the disease—has re-emerged with new positive results
Biogen to spend $700M to build its stake to 49.9% in biosims joint venture with Samsung fiercepharma
July 02, 2018
After Biogen reported first-quarter results back in April, CFO Jeff Cappello said the company would get further involved in an "attractive value creation" opportunity: its biosimiliars joint venture with Samsung BioLogics. Now, the drugmaker is disclosing
Biogen acquires licence for Japanese company TMS’ stroke drug pharmatimes
June 13, 2018
Biogen has signed an exclusive option agreement to buy Japan-based biotechnology company TMS’ TMS-007 drug candidate being developed for the treatment of acute ischemic stroke (AIS).
Biogen and Neurimmune Announce Option Exercise for Alzheimer’s Disease Investigational Treatment Aducanumab b3cnewswire
May 08, 2018
Biogen (Nasdaq: BIIB) and Neurimmune announced today that Biogen has exercised its option to further reduce the previously negotiated royalty rates payable on potential future sales of aducanumab...
Biogen to boost stake in biosims joint venture as competition to its MS meds mounts fiercepharma
April 28, 2018
With its important multiple sclerosis business facing off against growing competition, Biogen plans to get further involved in an "attractive value creation" prospect: a biosimilars ......
Biogen’s First Quarter Driven by MS Drugs and Spinraza biospace
April 25, 2018
Biogen saw a strong first quarter with 11 percent growth in revenues to $3.1 billion, which were spurred by gains in spinal muscular atrophy (SMA) treatment Spinraza and multiple sclerosis treatment Tecfidera.
Biogen and Ionis Tie Up in $1 Billion Deal to Develop Neurological Therapies biospace
April 23, 2018
Shares of Ionis Pharmaceuticals are up more than 10 percent in premarket trading after Biogenhanded over $1 billion to support a new 10-year collaboration agreement to develop novel antisense drug candidates for a broad range of neurological diseases.
Does Novartis’s Acquisition of AveXis Spell Trouble for Biogen? biospace
April 11, 2018
Switzerland-based Novartis is buying Bannockburn, Illinois-based AveXis for $8.7 billion. This could spell big trouble for Cambridge, Massachusetts-based Biogen.
Biogen, Bioepis resolve dispute over Humira biosimilar biospectrumasia
April 08, 2018
AbbVie will grant patent licenses for the biosimilar, branded as IMRALDI, in Europe on a country-specific basis.
Biogen, Bioepis resolve dispute over Humira biosimilar biospectrumasia
April 08, 2018
AbbVie will grant patent licenses for the biosimilar, branded as IMRALDI, in Europe on a country-specific basis.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page